That raises the question , if it’s an open label trial
with more sites being added, do the Management have a good idea already. Because they have flown all the experts in for a strategy meeting. Then announced Ph2 will start straight away. Maybe I’m reading to much into this but, it seems that bad news is highly unlikely before Ph2 results are out.
Especially given two streams of research into B cell vaccines have come together and approved Ph2.
How much knowledge do they have , which we don’t, when making our assessment here.
Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-68
-
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.7¢ | $388.1K | 10.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 146314 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 2536521 | 6 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
